2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome

Elias Jabbour, Srdan Verstovsek, Francis Giles, Varsha Gandhi, Jorge Cortes, Susan O'Brien, William Plunkett, Guillermo Garcia-Manero, C. Ellen Jackson, Hagop Kantarjian, Michael Andreeff

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Hypereosinophilic syndrome (HES) is a rare, disabling, and incurable disease. In this study, a combination of 2-chlorodeoxyadenosine (2-CdA) and cytosine arabinoside (ara-C) chemotherapy was evaluated in patients with HES. METHODS. Nine patients with HES were treated with ara-C (1 g/m 2) given intravenously over 2 hours at 0 hours, 48 hours, 72 hours, 96 hours, and 120 hours; and 2-CdA (12 mg/m2 per day) was given as a continuous intravenous infusion over 5 days starting at 24 hours. A second course of the same therapy was administered in patients who had a response. RESULTS. All patients had signs and symptoms of end-organ involvement. The median time from diagnosis to therapy was 25 months. Seven patients had received prior therapies. Five patients (55%) achieved a complete remission (CR), 1 after receiving 2 courses of therapy. Elimination of eosinophilia was accompanied by the resolution of symptoms. The median disease-free survival and overall survival after the diagnosis for patients who achieved CR was 26 months and 44 months, respectively. Treatment was tolerated well. Febrile neutropenia occurred in 28% of the 14 courses that were given. The median time to recovery from neutropenia and thrombocytopenia was 17 days and 39 days, respectively. CONCLUSIONS. The combined 2-CdA and ara-C chemotherapy regimen had activity in patients with HES.

Original languageEnglish (US)
Pages (from-to)541-546
Number of pages6
JournalCancer
Volume104
Issue number3
DOIs
StatePublished - Aug 1 2005
Externally publishedYes

Fingerprint

Cladribine
Hypereosinophilic Syndrome
Cytarabine
Therapeutics
Drug Therapy
Febrile Neutropenia
Eosinophilia
Neutropenia
Intravenous Infusions
Thrombocytopenia
Disease-Free Survival
Signs and Symptoms
Survival

Keywords

  • 2-Chlorodeoxyadenosine
  • Chemotherapy
  • Cytarabine
  • Hypereosinophilic syndrome

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Jabbour, E., Verstovsek, S., Giles, F., Gandhi, V., Cortes, J., O'Brien, S., ... Andreeff, M. (2005). 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer, 104(3), 541-546. https://doi.org/10.1002/cncr.21186

2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. / Jabbour, Elias; Verstovsek, Srdan; Giles, Francis; Gandhi, Varsha; Cortes, Jorge; O'Brien, Susan; Plunkett, William; Garcia-Manero, Guillermo; Jackson, C. Ellen; Kantarjian, Hagop; Andreeff, Michael.

In: Cancer, Vol. 104, No. 3, 01.08.2005, p. 541-546.

Research output: Contribution to journalArticle

Jabbour, E, Verstovsek, S, Giles, F, Gandhi, V, Cortes, J, O'Brien, S, Plunkett, W, Garcia-Manero, G, Jackson, CE, Kantarjian, H & Andreeff, M 2005, '2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome', Cancer, vol. 104, no. 3, pp. 541-546. https://doi.org/10.1002/cncr.21186
Jabbour, Elias ; Verstovsek, Srdan ; Giles, Francis ; Gandhi, Varsha ; Cortes, Jorge ; O'Brien, Susan ; Plunkett, William ; Garcia-Manero, Guillermo ; Jackson, C. Ellen ; Kantarjian, Hagop ; Andreeff, Michael. / 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. In: Cancer. 2005 ; Vol. 104, No. 3. pp. 541-546.
@article{4b087dd5d4a9465f9d633c39cc613994,
title = "2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome",
abstract = "BACKGROUND. Hypereosinophilic syndrome (HES) is a rare, disabling, and incurable disease. In this study, a combination of 2-chlorodeoxyadenosine (2-CdA) and cytosine arabinoside (ara-C) chemotherapy was evaluated in patients with HES. METHODS. Nine patients with HES were treated with ara-C (1 g/m 2) given intravenously over 2 hours at 0 hours, 48 hours, 72 hours, 96 hours, and 120 hours; and 2-CdA (12 mg/m2 per day) was given as a continuous intravenous infusion over 5 days starting at 24 hours. A second course of the same therapy was administered in patients who had a response. RESULTS. All patients had signs and symptoms of end-organ involvement. The median time from diagnosis to therapy was 25 months. Seven patients had received prior therapies. Five patients (55{\%}) achieved a complete remission (CR), 1 after receiving 2 courses of therapy. Elimination of eosinophilia was accompanied by the resolution of symptoms. The median disease-free survival and overall survival after the diagnosis for patients who achieved CR was 26 months and 44 months, respectively. Treatment was tolerated well. Febrile neutropenia occurred in 28{\%} of the 14 courses that were given. The median time to recovery from neutropenia and thrombocytopenia was 17 days and 39 days, respectively. CONCLUSIONS. The combined 2-CdA and ara-C chemotherapy regimen had activity in patients with HES.",
keywords = "2-Chlorodeoxyadenosine, Chemotherapy, Cytarabine, Hypereosinophilic syndrome",
author = "Elias Jabbour and Srdan Verstovsek and Francis Giles and Varsha Gandhi and Jorge Cortes and Susan O'Brien and William Plunkett and Guillermo Garcia-Manero and Jackson, {C. Ellen} and Hagop Kantarjian and Michael Andreeff",
year = "2005",
month = "8",
day = "1",
doi = "10.1002/cncr.21186",
language = "English (US)",
volume = "104",
pages = "541--546",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome

AU - Jabbour, Elias

AU - Verstovsek, Srdan

AU - Giles, Francis

AU - Gandhi, Varsha

AU - Cortes, Jorge

AU - O'Brien, Susan

AU - Plunkett, William

AU - Garcia-Manero, Guillermo

AU - Jackson, C. Ellen

AU - Kantarjian, Hagop

AU - Andreeff, Michael

PY - 2005/8/1

Y1 - 2005/8/1

N2 - BACKGROUND. Hypereosinophilic syndrome (HES) is a rare, disabling, and incurable disease. In this study, a combination of 2-chlorodeoxyadenosine (2-CdA) and cytosine arabinoside (ara-C) chemotherapy was evaluated in patients with HES. METHODS. Nine patients with HES were treated with ara-C (1 g/m 2) given intravenously over 2 hours at 0 hours, 48 hours, 72 hours, 96 hours, and 120 hours; and 2-CdA (12 mg/m2 per day) was given as a continuous intravenous infusion over 5 days starting at 24 hours. A second course of the same therapy was administered in patients who had a response. RESULTS. All patients had signs and symptoms of end-organ involvement. The median time from diagnosis to therapy was 25 months. Seven patients had received prior therapies. Five patients (55%) achieved a complete remission (CR), 1 after receiving 2 courses of therapy. Elimination of eosinophilia was accompanied by the resolution of symptoms. The median disease-free survival and overall survival after the diagnosis for patients who achieved CR was 26 months and 44 months, respectively. Treatment was tolerated well. Febrile neutropenia occurred in 28% of the 14 courses that were given. The median time to recovery from neutropenia and thrombocytopenia was 17 days and 39 days, respectively. CONCLUSIONS. The combined 2-CdA and ara-C chemotherapy regimen had activity in patients with HES.

AB - BACKGROUND. Hypereosinophilic syndrome (HES) is a rare, disabling, and incurable disease. In this study, a combination of 2-chlorodeoxyadenosine (2-CdA) and cytosine arabinoside (ara-C) chemotherapy was evaluated in patients with HES. METHODS. Nine patients with HES were treated with ara-C (1 g/m 2) given intravenously over 2 hours at 0 hours, 48 hours, 72 hours, 96 hours, and 120 hours; and 2-CdA (12 mg/m2 per day) was given as a continuous intravenous infusion over 5 days starting at 24 hours. A second course of the same therapy was administered in patients who had a response. RESULTS. All patients had signs and symptoms of end-organ involvement. The median time from diagnosis to therapy was 25 months. Seven patients had received prior therapies. Five patients (55%) achieved a complete remission (CR), 1 after receiving 2 courses of therapy. Elimination of eosinophilia was accompanied by the resolution of symptoms. The median disease-free survival and overall survival after the diagnosis for patients who achieved CR was 26 months and 44 months, respectively. Treatment was tolerated well. Febrile neutropenia occurred in 28% of the 14 courses that were given. The median time to recovery from neutropenia and thrombocytopenia was 17 days and 39 days, respectively. CONCLUSIONS. The combined 2-CdA and ara-C chemotherapy regimen had activity in patients with HES.

KW - 2-Chlorodeoxyadenosine

KW - Chemotherapy

KW - Cytarabine

KW - Hypereosinophilic syndrome

UR - http://www.scopus.com/inward/record.url?scp=22544463359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22544463359&partnerID=8YFLogxK

U2 - 10.1002/cncr.21186

DO - 10.1002/cncr.21186

M3 - Article

C2 - 15977212

AN - SCOPUS:22544463359

VL - 104

SP - 541

EP - 546

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -